Pfizer Inc. (NYSE: PFE) is a Healthcare company (Drug Manufacturers - General) with a market capitalization of $164.5B. The Maz Rating grades it against the other companies in its sector.
Pfizer Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $28.86, Pfizer Inc. trades at 40.8x trailing earnings, 2.6x sales and 1.8x book value, with an EV/EBITDA of 16.7. Over the last twelve months it generated about $63.6B of revenue and $4.0B of net income. It runs a gross margin of 73.4%, an operating margin of 23.8% and a net margin of 6.3%. It shows return on equity of 4.6%, return on invested capital of 8.3% and a free cash flow yield of 7.2%. On the balance sheet: a debt-to-equity ratio of 0.70 and a current ratio of 1.42. Over the past 52 weeks the share price ranged from $23.62 to $31.44, with a beta of 0.30.
Pfizer Inc. pays a dividend yielding 5.96%, with 243% of earnings paid out. Its Maz Dividend Score is 2.23 out of 5, ranked against the other dividend payers in its sector (Safety 1.23, Growth 2.03, Yield 4.77, Consistency 4.49).
40 Wall Street analyst ratings cover the stock: 16 Buy, 23 Hold and 1 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Pfizer Inc. (PFE) passes 2 of 5 published Shariah screening standards checked by Maz Vantage: it passes MSCI and FTSE, and fails AAOIFI, S&P Global and Dow Jones.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 38.4% / 30% · (Cash+Inv) / Mkt Cap (36m) 9.63% / 30% · Interest income / Revenue 0.65% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 38.4% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 8.74% / 33% · Receivables / Mkt Cap (36m) 8.69% / 49% · Interest income / Revenue 0.65% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 38.4% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 8.74% / 33.33% · Receivables / Mkt Cap (24m) 8.69% / 33.33% · Interest income / Revenue 0.65% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 31.1% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 6.41% / 33.33% · Receivables / Avg Assets (4Q) 6.71% / 33.33% · Interest income / Revenue 0.65% / 5% | Pass |
| FTSE | Debt / Total Assets 30.6% / 33.33% · (Cash+ST Inv) / Total Assets 6.98% / 33.33% · (Cash+Recv) / Total Assets 13.9% / 33.33% · Interest income / Revenue 0.65% / 5% | Pass |
It depends on the standard you follow. As of September 2026, Pfizer Inc. (PFE) passes 2 of 5 published Shariah screening standards checked by Maz Vantage: it passes MSCI and FTSE, and fails AAOIFI, S&P Global and Dow Jones.
No. Pfizer Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m).
About 0.65% of each dividend: Pfizer Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 27, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.